Portfolio company
Coneksis
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Coneksis develops xenogenic immunotherapy treatments for canine lymphoma and other veterinary oncology conditions for pet owners and veterinary health providers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
PetMedix
PetMedix develops species-specific monoclonal antibody therapeutics for companion animals to treat chronic and terminal diseases in dogs and cats.
LEAH Labs
This company develops gene-edited cell therapies for dogs with cancer for use by veterinarians.
FidoCure
The company provides genomic testing and AI-enabled personalised treatment recommendations for dogs with cancer to veterinarians and pet owners.
Gallant Therapeutics
This company develops mesenchymal stromal cell therapies for veterinary professionals to treat inflammatory diseases and promote tissue repair in cats and dogs.
DeepScan Diagnostics
This company develops cell-free DNA blood tests for veterinarians to detect cancer and monitor treatment response in dogs.
Gallant
The company develops ready-to-use mesenchymal stromal cell therapies for veterinary professionals to treat inflammatory diseases and promote tissue repair in cats and dogs.
PETDX
This company develops liquid biopsy blood tests for the early detection of cancer in dogs for use by veterinary professionals.
Aratana
This company develops and commercialises biopharmaceutical medicines for dogs and cats to treat conditions including pain and inappetence for the veterinary market.
